This article is more than 5 years old. Information may no longer be current.

Stemedica Cell Technologies, Lumenis enter into macular degeneration clinical study agreement

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN DIEGO — Stemedica Cell Technologies and Lumenis have entered into a collaboration agreement to initiate a clinical study evaluating a novel treatment for macular degeneration involving adult stem cells, according to a joint press release from the companies.

The 12-month study will begin in March and will examine the safety and efficacy of using Stemedica's Multiple Cell Technology stem cell lines in combination with the Lumenis SRT retinal laser for treating macular degeneration.

The study will be conducted at the Fyodorov Eye Institute in Moscow, and a parallel study will be performed at Hospital Angeles in Tijuana, Mexico, the release said.